NCT05625399 · Interventional trial
A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma
Overall registry status Active not recruiting
Phase 3
Conditions Melanoma
Delaware Valley sites
- Local Institution - 0124 · Philadelphia, PA · Philadelphia County
First posted
Registry updated
Added to the directory